Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Unum Therapeutics Inc. (UMRX)

2.34   0.09 (4%) 10-01 08:39
Open: 2.25 Pre. Close: 2.25
High: 2.401 Low: 2.25
Volume: 207,492 Market Cap: 99M
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The firm is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The firm's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The firm's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.404 - 2.413 2.413 - 2.423
Low: 2.227 - 2.237 2.237 - 2.247
Close: 2.324 - 2.341 2.341 - 2.359

Technical analysis

as of: 2020-09-30 4:47:29 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.17     One year: 3.64
Support: Support1: 2.05    Support2: 1.71
Resistance: Resistance1: 2.71    Resistance2: 3.12
Pivot: 2.57
Moving Average: MA(5): 2.32     MA(20): 2.51
MA(100): 1.86     MA(250): 1.20
MACD: MACD(12,26): -0.06     Signal(9): -0.02
Stochastic oscillator: %K(14,3): 16.87     %D(3): 19.44
RSI: RSI(14): 42.21
52-week: High: 3.72  Low: 0.29  Change(%): 62.5
Average Vol(K): 3-Month: 118023  10-Days: 39284

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
UMRX has closed above bottom band by 25.3%. Bollinger Bands are 10.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 30 Sep 2020
Unum Therapeutics Inc (UMRX) Stock Loses -12.77% This Week; Should You Buy? - InvestorsObserver

Thu, 17 Sep 2020
Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Wed, 16 Sep 2020
Unum Therapeutics Inc. (UMRX) Sold Its BOXR Technology to SOTIO - Stocks Register

Mon, 14 Sep 2020
Should You Buy Unum Therapeutics Inc (UMRX) Stock? - InvestorsObserver

Wed, 09 Sep 2020
Unum Therapeutics Inc (NASDAQ:UMRX) Completes a Transaction Focused on the BOXR Technology with SOTIO - BP Journal

Thu, 03 Sep 2020
12-month price target for Unum Therapeutics Inc. (NASDAQ:UMRX) now sits at $6 - Marketing Sentinel

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 42
Shares Float (M)
% Held by Insiders 35.40
% Held by Institutions 31.04
Shares Short (K) 988
Shares Short P. Month (K) 1,210

Stock Financials

EPS -0.860
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.500
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth -83.2
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -2.72
PEG Ratio
Price to Book value 4.68
Price to Sales
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.